Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients with Preexisting Cardiovascular Disease: Prespecified Analysis from EXSCEL

Robert J. Mentz, Vivian P. Thompson, David Aguilar, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Alice P. Kong, Peter Öhman, Naveed Sattar, Russell S. Scott, Yee Weng Wong, Rury R. Holman, Adrian F. Hernandez

Research output: Contribution to journalArticlepeer-review

14 Scopus citations
Original languageEnglish
Pages (from-to)2576-2578
Number of pages3
JournalCirculation
Volume138
Issue number22
DOIs
StatePublished - Nov 27 2018

Bibliographical note

Funding Information:
EXSCEL was sponsored and funded by Amylin Pharmaceuticals Inc (San Diego, CA), a wholly owned subsidiary of AstraZeneca (Gaithersburg, MD).

Keywords

  • cardiovascular diseases
  • outcome measures
  • pharmacotherapy
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients with Preexisting Cardiovascular Disease: Prespecified Analysis from EXSCEL'. Together they form a unique fingerprint.

Cite this